Ticktin Robert 4

What Happened

• Robert Ticktin, General Counsel and Chief Operating Officer of PMV Pharmaceuticals (PMVP), was granted 319,270 derivative securities on 2026-03-05. The reported acquisition price is $0, so the immediate reported value is $0; the award is a grant of derivative securities (not an open-market purchase or sale).

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (timely).
• Amount granted: 319,270 derivative shares; reported acquisition price: $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Vesting: These securities vest in 48 equal monthly installments beginning April 3, 2026 (per footnote).
• No sale, exercise, or tax-withholding reported in this filing; no 10b5-1 plan or late filing indicated.

Context

• This is a time-based equity award (derivative grant) subject to multi-year vesting. It represents potential future economic interest if and when the awards vest and convert to stock or are exercised; it does not reflect an immediate market purchase or sale.
• Awards like this are common as compensation and don’t by themselves indicate the insider is buying or selling stock for investment reasons — they do, however, increase potential future insider ownership if vesting conditions are met.